摘要
目的：探讨盐酸氨溴索对怠性加重期慢性阻塞性肺病（COPD）的临床疗效。方法：随机选择我院37例急性加重期COPD患者，20例为治疗组，17倒为对照组，两组在同样抗感染、常规对症治疗的基础上，治疗组加用盐酸氨溴索注射液治疗，两组均在一个疗程后评价疗效。结果：治疗组显效率75．0％（15／20），好转率20．0％（4／20）；对照组显效率41．2％（7／17），好转率47．1％，两组显效率和好转率比较均有显著性差异（P〈0．05）。两组有效率和不良反应比较差异没有显著性（P〉0．05）。结论：盐酸氨溴索能使急性加重期COPD患者临床症状、体征得到显著改善，在没有明显不良反应的情况下较常规治疗疗程短，值得临床推广应用。
Objective： To investigate clinical efficacy of ambroxol on acute exacerbation of COPD. Method： 20 patients were randomly selected for the treatment group among 37 cases of acute exacerbation of COPD, and 17 cases as control group. Both groups proceeded anti--infection, symptomatic treatment and others conventional treatment. On the basis of conventional treatment, treatment group received ambroxol hydrochloride injection treatment. Then, the clinical efficacy was evaluated. Results： The great improved rate in treatment group was 75.0% （15/20） and in control group was 41.2% （7/17）, improved rate in treatment group was 20.0% （4/20） and in control group was 47.1%. Compared both the great improved rate and improvement rate between two groups, the difference was significant （ P 〈0.05）. However, between two groups, there was no significant difference in the total efficiency and side effects （P〉 0.05）. Conclusions： Amhroxol could make the symptoms of acute exacerbation of COPD improve dramatically without obvious adverse reactions. Ambroxol could shorten the course of treatment and worth clinical application.
